The recent failure of Bristol-Myers Squibb's lung cancer immunotherapy to meet its primary endpoint demonstrates the challenge of working with imperfect biomarkers.
Results from the Rheumatoid Arthritis Responder Dream Challenge did not support the use of common SNP data to improve treatment response prediction models.
The gene expression assay, which targets 18 markers, is being used by Merck in three new Phase III clinical trials to expand the indication for Keytruda.
The test will identify NSCLC patients with PD-L1 expression who are likely to benefit from Merck's Keytruda, which has received a positive opinion from European regulators.
Merck is cutting some 360 jobs as it shifts resources to emerging areas of study, according to the In the Pipeline blog.
In a Science Translational Medicine opinion piece, a Merck executive suggests that universities offer money-back guarantees on their research.
Non-profit Exactis Innovation aims to create a repository of cancer tissue samples, as well as databases of genomic and clinical data from patients.
NanoString will develop and commercialize the diagnostic test to predict response to Merck's cancer immunotherapeutic antibody Keytruda.
Myriad's myChoice HRD companion diagnostic will be used to evaluate an investigational therapy combining Tesaro and Merck drugs for breast and ovarian cancer.
The study, which looked at markers of immune senescence in older patients, suggests the platform could be useful in diagnostic and companion diagnostic work.
The Wall Street Journal speaks with patients affected by questionable test results from Theranos.
Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.
Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.
In Science this week: convergent evolution in bird hemoglobin, and more.